Literature DB >> 8346973

Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome.

R H Hill1, S P Caudill, R M Philen, S L Bailey, W D Flanders, W J Driskell, M L Kamb, L L Needham, E J Sampson.   

Abstract

In late 1989, an epidemic of eosinophilia-myalgia syndrome (EMS) that resulted in several thousand cases of the syndrome and 36 deaths was recognized in the United States. Physicians in New Mexico linked the epidemic to the ingestion of L-tryptophan (LT). Results of studies indicated that one or more trace contaminants in LT were likely causes of the EMS epidemic. Investigators traced the LT that was taken by most patients with EMS to a single manufacturer, Showa Denko K.K. of Japan. We now report results of high performance liquid chromatographic analysis of LT samples from this manufacturer. Three sets of blind-coded samples were analyzed: the priority case lot set, which included 54 case-associated LT lots and 50 noncase-associated LT lots that were taken by case and control subjects who used only one brand of LT; the single lot case set, which included 73 case-associated LT lots and 25 noncase associated LT lots taken by case and control subjects who used only a single lot of LT; and the South Carolina tablet set, which included LT tablets taken by case subjects (n = 26) and by control subjects (n = 52). We statistically compared the concentration of each contaminant in case-associated, noncase-associated, and control samples of each sample set. The analyses showed that there were more than 60 minor contaminants in the LT from Showa Denko K.K., and that six of these contaminants were associated with EMS. The structures of three contaminants are known, but the identities of the other three contaminants are currently unknown.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346973     DOI: 10.1007/bf00230724

Source DB:  PubMed          Journal:  Arch Environ Contam Toxicol        ISSN: 0090-4341            Impact factor:   2.804


  15 in total

1.  3-anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples.

Authors:  Y Goda; J Suzuki; T Maitani; K Yoshihira; M Takeda; M Uchiyama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-08       Impact factor: 1.645

2.  Update: analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-11-02       Impact factor: 17.586

3.  Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-08-31       Impact factor: 17.586

4.  Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan.

Authors:  P A Hertzman; W L Blevins; J Mayer; B Greenfield; M Ting; G J Gleich
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

5.  Eosinophilia-myalgia syndrome--New Mexico.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-11-17       Impact factor: 17.586

6.  Eosinophilia-myalgia syndrome and L-tryptophan-containing products--New Mexico, Minnesota, Oregon, and New York, 1989.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-11-24       Impact factor: 17.586

7.  L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.

Authors:  L J Crofford; J I Rader; M C Dalakas; R H Hill; S W Page; L L Needham; L S Brady; M P Heyes; R L Wilder; P W Gold
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

8.  Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer.

Authors:  L Slutsker; F C Hoesly; L Miller; L P Williams; J C Watson; D W Fleming
Journal:  JAMA       Date:  1990-07-11       Impact factor: 56.272

9.  Tryptophan-associated eosinophilic connective-tissue disease. A new clinical entity?

Authors:  D J Clauw; D J Nashel; A Umhau; P Katz
Journal:  JAMA       Date:  1990-03-16       Impact factor: 56.272

10.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

Authors:  E A Belongia; C W Hedberg; G J Gleich; K E White; A N Mayeno; D A Loegering; S L Dunnette; P L Pirie; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

View more
  4 in total

1.  L-Tryptophan: Biochemical, nutritional and pharmacological aspects.

Authors:  E L Sainio; K Pulkki; S N Young
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

2.  Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.

Authors:  Jeffrey A Allen; Alicia Peterson; Robert Sufit; Monique E Hinchcliff; J Matthew Mahoney; Tammara A Wood; Frederick W Miller; Michael L Whitfield; John Varga
Journal:  Arthritis Rheum       Date:  2011-11

3.  Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.

Authors:  H Takagi; M S Ochoa; L Zhou; T Helfman; H Murata; V Falanga
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

4.  Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.

Authors:  J Adachi; M Gomez; C C Smith; E M Sternberg
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.